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Introduction: Eribulin mesylate (E7389) is an analog of halichon-
drin B with a unique mechanism of microtubule binding. The
activity and toxicity of eribulin were assessed in patients with
advanced non-small cell lung cancer (NSCLC) previously treated
with a taxane.
Methods: An open-label phase II study included patients with
NSCLC previously treated with platinum and taxane-based therapy,
with up to two prior cytotoxic regimens, given for metastatic disease
or as adjuvant therapy. Patients were stratified by taxane-sensitivity:
taxane-sensitive (TS, progression 90 days after taxane) or taxane-
resistant (TR, progression 90 days after taxane). Patients received
an intravenous infusion of eribulin at 1.4 mg/m2 on days 1 and 8
every 21 days. The primary end point was objective response rate
and secondary end points included progression-free survival and
overall survival.
Results: Sixty-six patients were accrued. The objective response
rate was 5% with a median duration of response of 7.8 months. In
the TS arm, 3 of 45 patients (7%) achieved a partial response and
another 11 of 45 (24%) achieved stable disease for at least 3 months,
whereas in the TR arm, no patients achieved a partial response and
4 of 21 (19%) achieved stable disease for at least 3 months. Median
progression-free survival was 2.9 months in the TS subgroup and 1.2
months in the TR subgroup. The median overall survival was 12.6
months in the TS subgroup and 8.9 months in the TR subgroup.
Toxicities were primarily hematologic; only two patients developed
grade 3 neuropathy.
Conclusions: Eribulin mesylate is well tolerated and demonstrates
activity in pretreated, TS NSCLC.
Key Words: Halichondrin B, Eribulin mesylate, Non-small cell
lung cancer, Taxane-refractory, Taxane-sensitive.
(J Thorac Oncol. 2012;7: 574–578)
Lung cancer is the second most common cancer diagnosedin the United States, with 222,520 estimated new cases in
2010.1 Standard first-line treatment for advanced non-small
cell lung cancer (NSCLC) is chemotherapy with a platinum-
based doublet. These lead to a predictable response rate of
approximately 30% and a median survival of 10 to 12
months.2 There is a growing list of Food and Drug Admin-
istration (FDA)-approved agents for use in the second- and
third-line treatment, including docetaxel,3 pemetrexed,4 and
erlotinib.5 Although these agents have offered modest im-
provements in survival and quality of life, lung cancer re-
mains the leading cause of cancer-related mortality in both
men and women.1
Taxanes such as docetaxel selectively bind to polym-
erized tubulin and promote polymerization, resulting in ab-
normal microtubule assembly.6 One clinical advantage of
taxanes over other therapies is their activity in tumors lacking
functional p53, which is relatively common in NSCLC.7
While docetaxel has demonstrated efficacy in first-line dou-
blets and as a single agent in subsequent lines of therapy,
resistance over time is inevitable. There is a pressing need to
explore new agents for patients whose cancer progresses on
available therapies.
Eribulin mesylate (E7389) is a tubulin-binding agent
that inhibits microtubule dynamics by mechanisms distinct
from taxanes. This synthetic analog of halichondrin B (a
substance isolated from the rare marine sponge Halichondria
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okadai8) has shown in vitro activity in taxane-resistant (TR)
cell lines.9 It was recently approved by the FDA for the
treatment of patients with metastatic breast cancer previously
treated with anthracycline and taxane therapy and at least two
prior regimens based on the phase III EMBRACE trial.10 This
trial randomized patients to eribulin mesylate or standard
therapy (most often vinorelbine, gemcitabine, or capecit-
abine). Analysis of the 762 patients enrolled demonstrated a
response rate of 11% and an improvement in overall survival
(OS) from 10.6 to 13.1 months. A first-in-human phase I
study of eribulin mesylate conducted by the California Can-
cer Consortium established a maximum tolerated dose of 1.4
mg/m2 and two patients with NSCLC achieved a response.11
In another phase I trial of eribulin mesylate in solid tumors,
one patient with NSCLC achieved an unconfirmed partial
response (PR) and three patients with NSCLC achieved stable
disease (SD).12
This single-arm, open-label phase II study conducted
by the California Cancer Consortium sought to determine the
safety and efficacy of eribulin mesylate administered as an
intravenous infusion at 1.4 mg/m2 on days 1 and 8 of a 21-day
cycle in patients with advanced NSCLC previously treated
with a taxane or taxane-based therapy and stratified by prior
response to taxane therapy as either taxane-sensitive (TS)
or -resistant (TR).
PATIENTS AND METHODS
Patient Eligibility
Patients were required to have histologically or cyto-
logically confirmed stage IIIB or IV NSCLC that was recur-
rent or had progressed after treatment. Patients were required
to have been previously treated with platinum-based therapy
and a taxane but could have received no more than two prior
cytotoxic chemotherapy regimens, given for either metastatic
disease or as adjuvant therapy. At least 4 weeks must have
elapsed since prior chemotherapy and at least 2 weeks must
have elapsed since palliative radiation therapy. Additional
key inclusion criteria included at least one measurable lesion
by Response Evaluation Criteria in Solid Tumors (RECIST
v1.0), age 18 years, Karnofsky performance status 60%,
and adequate end-organ function. Patients with grade 2 or
greater neuropathy, uncontrolled intercurrent illness, or brain
metastases who were untreated or still requiring steroids were
excluded from this trial.
This trial was reviewed, approved, and sponsored by the
Cancer Therapy Evaluation Program of the National Cancer
Institute (ClinicalTrials.gov, identifier NCT00400829) under a
contract with the California Cancer Consortium. The local
institutional review board at each participating institution
approved the protocol. All patients gave written, informed
consent.
Treatment
Eribulin mesylate was administered as a 1- to 2-minute
intravenous infusion at a dose of 1.4 mg/m2 on days 1 and 8
of a 21-day cycle. The dose was reduced to 1.2 mg/m2 for
subsequent cycles if any of the following occurred during the
previous cycle: grade 3 neutropenia for more than 7 days,
febrile neutropenia, grade 4 thrombocytopenia or grade 3
thrombocytopenia with bleeding or requiring transfusion, or
any grade 3 or 4 nonhematologic toxicity that returned to
grade 0 or 1 within 14 days. If any of the preceding occurred
after the first dose reduction, there was a subsequent dose
reduction to 1.0 mg/m2. A maximum of two dose reductions
were allowed per patient.
Day 8 treatment was held if the absolute neutrophil
count was 1.0  109/L or the platelet count was 75 
109/L. Doses that were held were deleted and not adminis-
tered at a later time. If a patient required a dose to be held, the
subsequent cycle was reduced by one dose level. Patients
requiring more than two dose reductions or a delay in therapy
by 3 weeks were removed from the study.
Premedication to prevent hypersensitivity reactions
was not required but prophylactic antiemetic therapy was
given. Colony stimulating factors were not administered
during the first course but in the event of febrile neutropenia,
use of colony stimulating factors was permitted for subse-
quent courses. Eribulin mesylate treatment continued until
unacceptable toxicity, disease progression, and investigator
decision that discontinuation of therapy was in the best
interest of the patient or withdrawal of consent.
Evaluation of Toxicity and Response
Toxicity was graded according to the Common Termi-
nology Criteria for Adverse Events (CTCAE) v3.0. Complete
blood count with differential and platelet count was per-
formed weekly; serum chemistry panels and physical exam-
inations were performed before the start of each new course.
Baseline tumor assessments were obtained within 4 weeks of
start of treatment by computed tomography or magnetic
resonance imaging scans of the chest, abdomen, and pelvis.
Subsequent radiographic evaluation was performed every 6
weeks. Tumor assessments were performed according to
RECIST v1.0 criteria and classified as complete response
(CR), PR, progressive disease, or SD. Tumor response of CR
or PR was confirmed by a second examination performed at
least 4 weeks after the criteria for response were met. Radio-
graphic response was assessed at the annual response review
of the California Consortium.
The objective response rate was defined as CR 
PR/(number of eligible patients); duration of CR or PR was
calculated as the time from which measurement criteria were
first met for CR or PR until the first date that recurrent or
progressive disease was objectively documented. Progres-
sion-free survival (PFS) was calculated as the time from the
start of treatment to the time of documented progression (per
RECIST criteria), symptomatic deterioration, or death; pa-
tients who were alive and had not yet progressed were
censored at their last follow-up. Six patients were taken off
treatment for reasons other than progression and subsequently
died of disease; for three of these patients, the date of
progression was taken as the date that the patient was taken
off treatment due to general deterioration. Two of these
patients died within 2 months. The remaining three patients
were censored at the time they were taken off treatment. OS
was calculated as the time from the start of treatment to death
from any cause or last follow-up.
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Study Design
Initial Design
All patients who began treatment with eribulin mesylate
were evaluated for toxicity; all eligible patients who began
treatment with eribulin mesylate were included in the analysis of
efficacy (response rate, PFS, and OS). A Simon optimum two-
stage design was used in this study, with objective response rate
as the primary efficacy end point. Secondary end points included
OS and toxicity profile. The study design was based on the fact
that a true response rate of 15% would indicate at least some
antitumor activity and would warrant further study of this
regimen, whereas a true response rate of 3% would not
warrant further study. Using this design, the probability of
correctly declaring that a true response rate of 15% warranted
further study was 0.90 (power). The probability of declaring that
an agent with only a 3% true response rate warranted further
study was 0.10 (alpha). In the first stage of accrual, 17 evaluable
patients were to be enrolled and assessed. If no response was
observed, then accrual would stop, with the conclusion that
single-agent eribulin mesylate was not promising for further
study in these patients. If one or more responses were seen in the
first 17 patients, an additional 22 patients would be accrued in
the second stage of the study. Three or more responses out of 39
patients would be considered as evidence warranting further
study of the regimen, providing other factors such as toxicity and
survival also appeared favorable. If only two responses out of 39
patients were observed, further study of eribulin mesylate in
these patients would not be warranted.
Patients were stratified based on their response to prior
taxane therapy. Patients were considered TS if they achieved a
sustained response or SD lasting at least 3 months with taxane-
based therapy used in the first- or second-line setting. All other
patients were labeled as TR. A subgroup analysis was planned to
evaluate the outcome of subjects considered TR and TS sepa-
rately. If no objective responses were observed among TR
patients in the first cohort, then consideration would be given to
closing accrual to this subset of patients.
Amendment to Extend Study
One objective response was observed in the first
17 patients. For administrative reasons, accrual continued to
41 patients instead of the planned 39. Three of the first 39
patients experienced a PR, suggesting activity of eribulin
mesylate. Further review of the three PRs revealed that one
patient, initially labeled TR, was more appropriately classi-
fied as TS. Thus, 3 of the 20 TS patients experienced a PR
while none of the 21 TR patients experienced an objective
response. Given this pattern, the study was subsequently
amended to enroll 25 additional TS patients to confirm the
favorable response rate in the TS subgroup while accrual to
the TR subgroup was halted.
RESULTS
Patient Characteristics
Between November 21, 2006, and December 4, 2009,
66 patients were accrued to this study, all of whom met the
key inclusion criteria and began treatment. There were 45
patients in the TS subgroup and 21 in the TR subgroup.
Patients received a median of two prior regimens (range,
1–2). Eight of the 66 patients (12%) received adjuvant treat-
ment and six of these patients received taxane-based adjuvant
therapy. Among the six patients treated with taxane in the
adjuvant setting, four were in the TS subgroup and two were
in the TR subgroup. The most common prior regimen was
carboplatin and paclitaxel, which was given to 68% of pa-
tients (41 of 66). Table 1 summarizes the baseline demo-
graphic and clinical characteristics of these patients, both
overall and by taxane sensitivity.
Study Drug Exposure
All 66 patients were treated with eribulin mesylate 1.4
mg/m2 on days 1 and 8 of a 21-day cycle. A total of 290
cycles of treatment was given to the 66 patients, with a
median number of four cycles per patient (range, 1–23) as
summarized in Table 1. The median number of cycles re-
ceived was 4 in the TS group (range, 1–23) and 2 in the TR
group (range, 1–8). Only one patient discontinued therapy
due to neuropathy (grade 3) and this was after nine cycles of
treatment. Treatment was held or reduced in only four other
patients for the following reasons: grade 4 neutropenia (one
day 8 dose was held, no further interruptions or reductions);
grade 3 neutropenia and thrombocytopenia; grade 3 consti-
pation, abdominal pain, and hyponatremia; and grade 4 in-
TABLE 1. Patient Demographics, Clinical Characteristics,
and Treatment Delivered
Characteristic
Taxane-Sensitive Taxane-Resistant Overall
No. of
Patients %
No. of
Patients %
No. of
Patients %
Total number of
patients
45 21 66
Age at study entry, yr
60 13 29 13 62 26 39
60 32 71 8 38 40 61
Median 65 55 63
Range 42–79 35–83 35–83
Gender
Female 23 51 12 57 35 53
Male 22 49 9 43 31 47
Histologic subtype
Adenocarcinoma 28 62 4 19 32 49
Squamous cell 5 11 5 24 10 15
Other, non-small
cell
12 27 12 57 24 36
Performance status
Karnofsky 60–80 21 47 8 38 29 44
Karnofsky 80–100 24 53 13 62 37 56
Cycles of therapy given
1 4 9 3 14 7 11
2 10 22 12 57 22 33
3 31 69 6 29 37 56
Median 4 2 4
Range 1–23 1–8 1–23
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somnia and fatigue. There were no reports of acute infusional
reactions during the administration of eribulin mesylate.
Efficacy
Tumor Response
Of the 66 patients, all were included in the assessment
of response. Table 2 summarizes the best response achieved.
No objective response was noted in the TR group but 29%
achieved SD and 19% maintained SD for at least 3 months. In
the TS group, 3 patients achieved PR (7%) and 27 achieved
SD (60%), and 22% maintained SD for at least 3 months.
There was no association between histologic subtype and
response (data not shown). Median PFS was 1.2 months for
the TR group and 2.9 months for the TS group. Eighteen of
the 21 patients in the TR group and 36 of the 45 in the TS
group had died at the time of this report. Median OS was 8.9
months in the TR group (95% CI: 5.0–15.4 months) and 12.6
months in the TS group (95% CI: 9.9–17.5 months). When
stratified by taxane sensitivity, there was no significant dif-
ference in PFS or OS between patients treated with a taxane
in the adjuvant setting and those treated in the metastatic
setting.
Duration of Response
The median duration of response for the three patients
who achieved PR was 7.8 months (5.7, 7.8, and 11.4 months).
Eighteen of the 33 patients with SD (55%) had their disease
stable for 3 months (median, 1.6 months; range, 0.4–2.9
months) and 15 (45%) had their disease stable for 3 months
or longer (median, 5.1 months; range, 3.0–11.4 months) since
the first disease assessment after treatment start. One patient
in the TR group had SD for 9.8 months and four patients in
the TS group had SD for more than 6 months.
Treatment Administered and Adverse Effects
The toxicity of eribulin mesylate was manageable, with
dose modification primarily due to myelosuppression. Table
3 summarizes the unlikely, possibly, probably, or definitely
treatment-related adverse events in all 66 patients who re-
ceived at least one dose of treatment. The most common
adverse effects were myelosuppression, constitutional symp-
toms (most commonly fatigue), metabolic/laboratory abnor-
malities (most commonly grade 1 elevations in liver function
tests and glucose), gastrointestinal toxicities (most commonly
grade 1 anorexia and nausea), neurologic toxicities (most
TABLE 2. Best Overall Tumor Response in
Eligible Population
Best Overall
Response
Taxane-
Sensitive
Taxane-
Resistant Overall
No. of
Patients %
No. of
Patients %
No. of
Patients %
Total number of
patients
45 21 66
Best response
PR 3 7 0 0 3 5
SD 27 60 6 29 33 50
PD 12 27 13 62 25 38
N/A 3 7 2 10 5 8
Overall survival, mo
Median (95% CI) 12.6 (9.9–17.5) 8.9 (5.0–15.4) 11.6 (8.2–13.7)
Progression free
survival, mo
Median (95% CI) 2.9 (2.5–4.8) 1.2 (1.1–2.9) 2.7 (1.3–3.9)
Follow-up, mo
Median (range) 39.5 (1.3–41.6) 38.1 (0.7–38.1) 38.1 (0.7–41.6)
PR, partial response; SD, stable disease; PD, progressive disease; CI, confidence
interval.
TABLE 3. Treatment-Related Adverse Events of Interest or
with an Incidence 10% by CTCAE Grade (n  66)
Adverse Event
Grade 1 or 2 Grade 3 or 4 All Grades
No. of
Patients %
No. of
Patients %
No. of
Patients %
Hematologic
Anemia 43 65 0 0 43 65
Leukopenia 22 33 19 29 41 62
Neutropenia 5 8 36 55 41 62
Thrombocytopenia 6 9 1 2 7 11
Constitutional
Fatigue 36 55 6 9 42 64
Fever, in the absence
of neutropenia
6 9 1 2 7 11
Dermatologic
Alopecia 13 20 0 0 13 20
Rash 7 11 0 0 7 11
Gastrointestinal
Anorexia 23 35 0 0 23 35
Constipation 13 20 3 5 16 24
Mucositis 9 14 0 0 9 14
Nausea 15 23 3 5 18 27
Vomiting 7 11 2 3 9 14
Lymphatics
Edema (limb) 10 15 0 0 10 15
Metabolic/laboratory
ALT (SGPT) 10 15 0 0 10 15
AST (SGOT) 14 21 0 0 14 21
Albumin (low) 16 24 1 2 17 26
Alkaline phosphatase 11 17 0 0 11 17
Glucose (high) 26 39 1 2 27 41
Potassium (low) 6 9 2 3 8 12
Sodium (low) 9 14 3 5 12 18
Neurologic
Neuropathy, sensory 18 27 2 3 20 30
Dizziness 7 11 2 3 9 14
Pain
Abdominal pain 6 9 2 3 8 12
Muscle pain 9 14 0 0 9 14
Pulmonary/upper
respiratory
Cough 9 14 0 0 9 14
Dyspnea 7 11 1 2 8 12
The toxicities defined as unrelated related to treatment were excluded.
ALT, alanine aminotransferase; AST, aspartate transaminase.
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commonly grade 1 neuropathy), and pain. Most of these
toxicities were grade 1 or 2. The most common grade 3 or 4
adverse effect was myelosuppression, particularly neutrope-
nia (55% of patients), although only one patient had grade 3
febrile neutropenia. Following eribulin mesylate therapy,
there were no reported cases of grade 4 neuropathy and only
two cases of grade 3 neuropathy (3%), both of which were
sensory in nature. There were no cases of grade 3 or 4 cranial
or motor neuropathies reported. There were no treatment-
related deaths.
DISCUSSION
This phase II study demonstrates the potential benefit of
eribulin mesylate in patients with NSCLC pretreated with a
taxane. Although the response rate in this patient population
was low (5% overall; 7% in the TS group; and 0% in the TR
group), a sizable number of patients achieved stable disease
(33 of 66, 50% overall; 60% in the TS group; and 29% in the
TR group). A more telling measure of benefit is maintenance
of stable disease for at least 3 months, and while fewer
patients met this benchmark (15 of 66, 23% overall; 24% in
the TS group; and 19% in the TR group), there was still some
indication of activity. This suggests a “clinical benefit rate”
(CBR, defined here as CR PR SD maintained for at least
3 months) of 27% overall (95% CI: 17–40%), higher in the
TS group (31%) than in the TR group (19%). It is important
to note that this was not a prespecified end point in this trial
and should be examined closely in future studies. The clinical
benefit of eribulin mesylate was seen in both TS and TR
subgroups; however, response was only noted in the TS
cohort and the benefit of therapy was far greater in these
patients. The outcomes of patients treated with a taxane in the
adjuvant setting were not significantly different from those
who received a taxane in the metastatic setting when stratified
by taxane sensitivity. Future studies limited to or stratified by
taxane sensitivity may have a greater likelihood of demon-
strating clinical benefit.
Eribulin mesylate was well tolerated in this trial of
pretreated patients. Neuropathy is a concern, given the similar
target of eribulin mesylate and taxanes and the history of
taxane therapy in all patients; however, only 2 of 66 patients
reported grade 3 sensory neuropathy (3%). The most com-
mon adverse effect was myelosuppression, specifically leu-
kopenia and neutropenia; however, only one patient reported
febrile neutropenia.
The activity of eribulin mesylate in patients with breast
cancer led to its FDA approval late last year. In the phase II
trial of eribulin mesylate in patients with taxane-pretreated,
metastatic breast cancer, the reported response rate was 9.3%
with a CBR of 17.1%.13 A similar response rate (9.7%) was
noted in a previously reported phase II trial in patients with
NSCLC; however, prior taxane therapy was not required in
that study.14 In contrast, the study reported here required prior
taxane therapy and stratified patients based on their response
to taxane therapy. The results demonstrate a clear difference
in activity in patients based on their resistance or sensitivity
to taxane therapy. Although prior taxane therapy did not
preclude activity of eribulin mesylate, prior taxane resistance
did decrease the likelihood of benefit, and no patients with
TR disease achieved a response to eribulin mesylate.
Our study strongly suggests a benefit of eribulin mesylate
in patients with advanced NSCLC previously treated with tax-
ane therapy, particularly in patients whose disease was initially
TS. Adverse effects were manageable with a surprisingly low
rate of peripheral neuropathy. In addition, no infusional
reactions were noted and premedication was not required.
Although the response rate is modest, a significant number of
patients did achieve disease control or SD. Based on its
tolerability and the signal of activity, further efforts to define
the role of eribulin mesylate in the treatment of advanced
NSCLC are warranted and trials in combination with other
agents are ongoing.
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